We examined the effect of a clove (Syzygium aromaticum) administered by two different routes on Candida albicans growth. using a murine oral candidiasis model.When the clove preparation was administered into the oral cavity of Candida-infected mice. their oral symptoms were improved and the number of viable Candida cells in the cavity was reduced. In contrast. when the clove preparation was administered intragastrically. oral symptoms were not improved.but viable cell numbers of Candida in the stomach and feces were decreased. These findings demonstrate that oral intake of an herbal food. clove. may suppress the overgrowth of C. albicans in the alimentary tract including the oral cavity.
Recently we and our colleagues examined anti-Candida activity of spices and herbs and reported that a clove preparation inhibited mycelial growth of C. albicans in vitro. then suggested its therapeutic availability against Candida colonization in mucosal tissues9,10) Clove is a well known spice. and is used as an aroma additive in food. pharmaceuticals. and cosmeticsll). Here. we examined the therapeutic efficacy of a clove preparation in a murine oral candidiasis model12). to Japan. The dried cloves were milled into fine powder and suspended in distilled water for administration. The content of dry matter in the clove preparation was measured after the weight decreased by drying at 37C. Eugenol was purchased from Wako Pure Chemical Industries. Ltd. (Osaka. Japan) and dissolved in dimethylsulfoxide (DMSO) at 10% w/w concentration prior to dilution with RP medium for in vitro experiments13)
Materials and

Measurement of in vitro activities of clove and eugenol against Candida growth
Measurement of inhibition of yeast form growth of Candida was performed as described previously14). C. albicans was grown on YPG medium (1% Bacto pepton. 0.5% yeast extract. 2% glucose. pH 6.5) for 16h at 37C with shaking at 38rpm. and the cells were collected by centrifugation (3,000rpm. 5min). After the supernatant was removed. the cells were washed twice with RP medium and the cell suspension was prepared in the same medium at 5X104 cells/ml. Clove preparation. eugenol in DMSO and DMSO (control) were diluted with RP medium. respectively. Each well of a 96-well flat bottom microplate received a mixture of 100 Ll of Candida cell suspension and 100ul of dilutions of clove preparation. eugenol in DMSO or DMSO. and the microplate was incubated for 16h at 37C in a 5% C02 atmosphere.
To determine the extent of mycelial growth of C. albicans. the crystal violet (CV) staining assay was performed as described previously15). Briefly. the medium in the wells was discarded. and then the adhesive Candida mycelia were sterilized by treatment with 70% ethanol. The mycelia were stained with 0.01% CV and washed with water. After the microplate was dried. 150 iii of isopropanol containing 0.04N HCl and 50ul of 0.25% sodium dodecyl sulfate were added to the wells and mixed. The absorbance at 620nm of duplicate samples was measured spectrophotometrically. The extent of total growth (including growth forms of both mycelium and yeast) of C. albicans was determined using the broth microdilution method. The Candida cells obtained by centrifuge (1,500 rpm. 5min. 4C) of a culture broth in each well were washed twice and suspended in sterile saline. The cell suspension was inoculated on Candida GS agar plate after serial 10-fold dilution. and the plate was incubated for 20h at 37C. The CFU were counted and the totals per well were calculated.
Animals
All animal experiments were performed according to the guidelines for the care and use of animals approved by Teikyo University. Six weekold female ICR mice (Charles River Japan. Inc.. Yokohama. Kanagawa) were used for all animal experiments. (The average body weight of mice was 25.5g at the beginning of the experiments.) The photoperiods were adjusted to 12h of light and 12h darkness daily. and the environmental temperature was constantly maintained at 21C. The mice were kept in cages housing 5-6 animals and were given food and water ad libitum. The experimental procedure of the oral candidiasis model in mice was described previouslyg). Briefly. immunosuppressed mice were induced by subcutaneous treatment with a dose of 100mg/kg of prednisolone (Mitaka Pharmaceutical Co.. Japan) 1 day prior to oral infection. Tetracycline hydrochloride (Takeda Shering Purau Animal Health Co.. Japan) in drinking water at a dose of 0.08% was given to the mice. beginning 1 day before infection. The animals were anesthetized by intramuscular injection with 100ul of 0.2% chlorpromazine chloride (Wako Pure Chemical Industries. Ltd.) in the foot. They were orally infected with about 5X107 cells/ml viable cells of C. aibicans TIMM 2640 in RP medium. Oral infection was performed by means of a cotton swab (baby cotton buds; Johnson & Johnson Co.. Tokyo) rolled in all parts of the mouth. The cell number of Candida inoculated in the oral cavity was calculated to be about 1X106cells/mouse by the difference in viable cell number associated with cotton swabs before and after oral inoculation.
Clove treatment
Clove powder suspended in distilled water was applied to Candida infected mice using a top-rounded needle for administration 3hour. 21hour. 27hour. 45hour. 51hour and 69hour after C. albicans inoculation by two alternative methods: 1. spreading 50ul per mouse of the clove suspension on and around the tongue and in the oral cavity. 2. injecting 200ul per mouse intragastrically.
GC analysis
The eugenol contents of clove preparations were analyzed by gas chromatography (GC) using a Hewlett-Packard model HP 6890. equipped with a DB-WAX column (J & W) (30mX0.25mm. 0.25um film thickness) and a flame ionization detector (Fm) 16, 17) .
Scoring of tongue's fur and squamous layer and quantification of oral infection
Scoring of tongue's fur was performed as described previously8). On the 3rd day after inoculation. groups of mice were sacrificed. and the fur of each tongue and squamous disorder was scored as follows: 0. normal; 1. fur in less than 20%; 2. fur in more than 21% but less than 90%; 3. fur in more than 91% and the squamous layer; 4. thick fur in more than 91% and the squamous layer.
Measurement of the number of viable Candida cells in each part of a mouse
The oral cavity (i.e. cheek. tongue. and soft palate) was swabbed by a cotton swab. After swabbing. the cotton end was cut off and placed in a tube containing 5ml sterile saline. The yeast cells were resuspended by mixing on a vortex mixer before culture in 100-fold dilution on a Candida GS plate for 20h at 37C. the CFU were counted. and the totals per swab were calculated. The stomach was cut out of a sacrificed mouse. washed with sterile PBS to remove its contents and homogenized in a tube containing 20ml sterile PBS. The homogenates were inoculated on Candida GS plates after serial 10-fold dilution with sterile saline. After incubation for 20h at 37C. the CFU were counted and the totals per mouse were calculated.Fresh feces from a mouse were placed in a tube containing 1ml sterile saline and suspended on a vortex mixer. Serial 10fold dilutions of the suspension were inoculated on a Candida GS plate. Using the procedure described above. the total per g of feces was calculated.
Statistical analysis
The data of scores were compared using the non-parametric
Mann-Whitney U test. 
Results
Growth
inhibitory activities of clove and eugenol against C. albicans in vitro Table 1 shows the activities of clove preparation and eugenol on the mycelial growth of C. albicans. The activities were measured by CV staining assay. The IC 50 of the clove preparation (0.415-2.04mg/ml) was about 10 times larger than that of eugenol (0.0408-0.204mg/ml). Eugenol is known to be the main component of clove's essential oil. The eugenol content in this clove preparation (0.415mg/ml) was measured by GC analysis to be 0.0615mg/ml. per gram of dry matter. Table 1 also shows the Table 1 . Activities of clove and eugenol to mycelial and total growth of C. albicans Activities were measured by the CV staining method as described in Materials and Methods. The concentration of 50% inhibition (IC 50) against Candida growth is indicated as the range between two concentrations. The total growth includes both growth forms of mycelium and yeast. The content of eugenol in clove preparations is shown in parenthesis.
activity on the total growth of C. albicans measured by counting Candida CFU. The IC5o of clove preparation on the total growth (0.415-2.04mg/ml) was in the same range as that on the mycelial growth. However. the IC5o of eugenol on the total growth (0.204-1.02mg/ml) was equal to or larger than that on the mycelial growth ( as depicted in Fig. 1B . The tongues orally treated with the clove preparation (10.38 mg/mouse) appeared normal and healthy ( Fig.  10 .
By histological studies. PAS-positive fungi could be observed in the lesions near the oral epithelium of dorsal tongues of the non-treated mice as shown in Fig. 2A .
There was no PAS-positive fungal hypha in the tongue of mice treated with the clove preparation ( Fig. 2B) . Table 2 shows that oral treatment with 10.38mg of clove preparation protected the mice from oral infection of Candida. estimated by the reduced clinical score of tongues and the lower number of CFU recovered from the oral cavity. while a dosage below 2.08mg/ml of clove preparation was less effective. Table 2 also shows that oral administration of clove did not decrease the viable Candida cells in stomachs or feces.
Effect of intragastric administration of clove preparation on intestinal growth of Candida albi cans
To examine its effect on the intestinal tract. clove preparation was administered directly into the stomachs of orally Candida infected mice. Table 3 shows that when the preparation was administered intragastrically at a dose of 41.5 mg/mouse to orally Candida-infected mice. the number of viable Candida cells in stomachs and feces was decreased. However. the clinical scores of tongues and the number of Candida of oral cavities were not improved as shown. such as studies on the optimal conditions in dosage and administration period of clove samples. and on a biological analysis of interaction between clove preparation and lingual mucosa. We wish to emphasize that our studies described here suggest the possible application of clove preparation as a spice in our dietary life to control the overgrowth of C. albicans in alimentary tracts including the oral cavity. Now we hope that our study will facilitate the development of a functional food for improvement of intestinal candidiasis in immunocompromised patients or elderly people using spices and herbs.
Discussion
